DE69728581D1 - Thiazolylbenzofuranderivate und ihre Verwendung als SRS-A- und Leukotrien-Antagonisten - Google Patents

Thiazolylbenzofuranderivate und ihre Verwendung als SRS-A- und Leukotrien-Antagonisten

Info

Publication number
DE69728581D1
DE69728581D1 DE69728581T DE69728581T DE69728581D1 DE 69728581 D1 DE69728581 D1 DE 69728581D1 DE 69728581 T DE69728581 T DE 69728581T DE 69728581 T DE69728581 T DE 69728581T DE 69728581 D1 DE69728581 D1 DE 69728581D1
Authority
DE
Germany
Prior art keywords
srs
leukotriene antagonists
thiazolylbenzofuran
derivatives
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69728581T
Other languages
German (de)
English (en)
Inventor
Masaaki Matsuo
Kazuo Okumura
Shinji Shigenaga
Hiroaki Nishimura
Hiroshi Matsuda
Daijiro Hagiwara
Tadashi Terasaka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujisawa Pharmaceutical Co Ltd
Original Assignee
Fujisawa Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9601235.6A external-priority patent/GB9601235D0/en
Priority claimed from AUPO1111A external-priority patent/AUPO111196A0/en
Application filed by Fujisawa Pharmaceutical Co Ltd filed Critical Fujisawa Pharmaceutical Co Ltd
Application granted granted Critical
Publication of DE69728581D1 publication Critical patent/DE69728581D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE69728581T 1996-01-22 1997-01-17 Thiazolylbenzofuranderivate und ihre Verwendung als SRS-A- und Leukotrien-Antagonisten Expired - Lifetime DE69728581D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9601235.6A GB9601235D0 (en) 1996-01-22 1996-01-22 Novel compounds
AUPO1111A AUPO111196A0 (en) 1996-07-18 1996-07-18 Novel compounds

Publications (1)

Publication Number Publication Date
DE69728581D1 true DE69728581D1 (de) 2004-05-13

Family

ID=25645218

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69728581T Expired - Lifetime DE69728581D1 (de) 1996-01-22 1997-01-17 Thiazolylbenzofuranderivate und ihre Verwendung als SRS-A- und Leukotrien-Antagonisten
DE69712042T Expired - Fee Related DE69712042T2 (de) 1996-01-22 1997-01-17 Thiazolylbenzofuranderivate und pharmazeutische zusammensetzungen die sie enthalten

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69712042T Expired - Fee Related DE69712042T2 (de) 1996-01-22 1997-01-17 Thiazolylbenzofuranderivate und pharmazeutische zusammensetzungen die sie enthalten

Country Status (12)

Country Link
US (1) US5994378A (enExample)
EP (2) EP0880519B1 (enExample)
JP (1) JP2000503984A (enExample)
KR (1) KR19990076788A (enExample)
CN (1) CN1209809A (enExample)
AT (2) ATE216384T1 (enExample)
CA (1) CA2244189A1 (enExample)
DE (2) DE69728581D1 (enExample)
EA (1) EA199800650A1 (enExample)
ES (1) ES2171878T3 (enExample)
HU (1) HUP9900424A2 (enExample)
WO (1) WO1997027190A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9919413D0 (en) 1999-08-18 1999-10-20 Zeneca Ltd Chemical compounds
WO2001032621A1 (en) * 1999-10-29 2001-05-10 Wakunaga Pharmaceutical Co., Ltd. Novel indole derivatives and drugs containing the same as the active ingredient
IL158168A0 (en) * 2001-04-16 2004-03-28 Tanabe Seiyaku Co 5-membered, nitrogen-containing heterocyclic compounds and pharmaceutical compositions containing the same
BRPI0211844B8 (pt) 2001-08-10 2021-05-25 Nippon Chemiphar Co composto de ácido fenóxi-acético ou um de seus sais farmaceuticamente aceitáveis, e, composição farmacêutica
CN1293076C (zh) 2001-10-12 2007-01-03 日本化学医药株式会社 过氧化物酶体增殖剂应答性受体δ的活化剂
US8013006B2 (en) * 2004-07-14 2011-09-06 Ptc Therapeutics, Inc. Methods for treating hepatitis C
AU2005296305A1 (en) * 2004-10-12 2006-04-27 Decode Genetics Ehf Sulfonamide peri-substituted bicyclics for occlusive artery disease
WO2006046683A1 (en) * 2004-10-25 2006-05-04 Astellas Pharma Inc. Thiazolylbenzofuran derivatives as leukotriene and prostaglandin d2 receptor antagonists
US8399666B2 (en) 2005-11-04 2013-03-19 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
US7977359B2 (en) 2005-11-04 2011-07-12 Amira Pharmaceuticals, Inc. 5-lipdxygenase-activating protein (FLAP) inhibitors
GB2431927B (en) * 2005-11-04 2010-03-17 Amira Pharmaceuticals Inc 5-Lipoxygenase-activating protein (FLAP) inhibitors
CN101460458A (zh) * 2006-02-15 2009-06-17 阿勒根公司 具有1－磷酸－鞘氨醇(s1p)受体拮抗剂生物活性的带芳基或者杂芳基基团的吲哚－3－羧酸的酰胺、酯、硫代酰胺和硫羟酸酯化合物
ES2461268T3 (es) * 2006-02-15 2014-05-19 Allergan, Inc. Compuestos de amida, éster, tioamida y tioléster de ácido indol-3-carboxílico que portan grupos arilo o heteroarilo que tienen actividad biológica antagonista del receptor de esfingosina-1-fosfato (S1P)
JP5290749B2 (ja) 2006-04-18 2013-09-18 日本ケミファ株式会社 ペルオキシソーム増殖剤活性化受容体δの活性化剤
DE102006021733A1 (de) * 2006-05-09 2007-11-22 Bayer Healthcare Ag 3-Tetrazolylindazole und 3-Tetrazolylpyrazolopyridine sowie ihre Verwendung
EP2027117A2 (en) * 2006-05-16 2009-02-25 Decode Genetics EHF Process for preparing 7-(acryloyl)-indoles
DE102006043443A1 (de) * 2006-09-15 2008-03-27 Bayer Healthcare Ag Neue aza-bicyclische Verbindungen und ihre Verwendung
AU2008206495A1 (en) * 2007-01-11 2008-07-24 Allergan, Inc. 6-substituted indole-3-carboxylic acid amide compounds having Sphingosine-1-Phosphate (S1P) receptor antagonist biological activity
US8524917B2 (en) 2007-01-11 2013-09-03 Allergan, Inc. 6-substituted indole-3-carboxylic acid amide compounds having sphingosine-1-phosphate (S1P) receptor antagonist biological activity
EP2277874B1 (en) 2008-04-15 2018-06-27 Nippon Chemiphar Co., Ltd. Activator for peroxisome proliferator-activated receptor
US8546431B2 (en) 2008-10-01 2013-10-01 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
DE102008063992A1 (de) 2008-12-19 2010-09-02 Lerner, Zinoviy, Dipl.-Ing. Neue aliphatisch substituierte Pyrazolopyridine und ihre Verwendung
CN104710385B (zh) 2010-03-12 2018-11-09 奥默罗斯公司 Pde10抑制剂以及相关组合物和方法
CN103649079B (zh) 2010-12-22 2016-11-16 Abbvie公司 丙型肝炎抑制剂及其用途
KR20150119871A (ko) 2013-02-21 2015-10-26 아드베리오 파마 게엠베하 메틸 ｛4,6-디아미노-2-[1-(2-플루오로벤질)-1H-피라졸로[3,4-b]피리디노-3-일]피리미디노-5-일｝메틸 카르바메이트의 형태
NZ630803A (en) 2014-04-28 2016-03-31 Omeros Corp Optically active pde10 inhibitor
NZ716494A (en) 2014-04-28 2017-07-28 Omeros Corp Processes and intermediates for the preparation of a pde10 inhibitor
WO2016033445A1 (en) * 2014-08-29 2016-03-03 Chdi Foundation, Inc. Probes for imaging huntingtin protein
AU2016250843A1 (en) 2015-04-24 2017-10-12 Omeros Corporation PDE10 inhibitors and related compositions and methods
US9920045B2 (en) 2015-11-04 2018-03-20 Omeros Corporation Solid state forms of a PDE10 inhibitor
KR102349776B1 (ko) 2017-11-17 2022-01-10 셀릭스 바이오 프라이빗 리미티드 눈 질환의 치료를 위한 조성물 및 방법

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2600644B2 (ja) * 1991-08-16 1997-04-16 藤沢薬品工業株式会社 チアゾリルベンゾフラン誘導体
JPH07179856A (ja) * 1993-12-21 1995-07-18 Canon Inc 液晶性化合物、これを含有する液晶組成物、該液晶組成物を用いた液晶素子並びにこれらを用いた表示方法、表示装置

Also Published As

Publication number Publication date
HUP9900424A2 (hu) 1999-05-28
CA2244189A1 (en) 1997-07-31
CN1209809A (zh) 1999-03-03
JP2000503984A (ja) 2000-04-04
DE69712042D1 (de) 2002-05-23
ATE263561T1 (de) 2004-04-15
EP1170009B1 (en) 2004-04-07
KR19990076788A (ko) 1999-10-15
ATE216384T1 (de) 2002-05-15
DE69712042T2 (de) 2002-10-02
EP1170009A3 (en) 2002-01-16
ES2171878T3 (es) 2002-09-16
EA199800650A1 (ru) 1999-02-25
US5994378A (en) 1999-11-30
EP0880519A1 (en) 1998-12-02
EP0880519B1 (en) 2002-04-17
WO1997027190A1 (en) 1997-07-31
EP1170009A2 (en) 2002-01-09

Similar Documents

Publication Publication Date Title
ATE263561T1 (de) Thiazolylbenzofuranderivate und ihre verwendung als srs-a- und leukotrien-antagonisten
DE69910831D1 (de) Epothilonderivate und ihre verwendung als antitumormittel
DE69721008D1 (de) Bicyclische pyrimidine derivate und ihre verwendung als antikoagulantien
DE69328975D1 (de) Aminomethylen substituierte heterocyclische verbindungen und ihre verwendung alssubstanz p antagonisten
LV12047A (lv) Kondenseti pirimidina atvasinajumi un to lietosana par angiotenzina II antagonistiem
ATE450515T1 (de) Anilinopyrimidinderivate als ikk?inhibitoren, und hiermit in zusammenhang stehende zusammensetzungen und verfahren
ATE171068T1 (de) Chinoloncarbonsäurederivate, ihre herstellung und ihre verwendung als zelladhäsion inhibitoren
DE69716925D1 (de) Isoxazoline derivate und ihre verwendung als antimikroben
DE69021639D1 (de) Disäuren von Diarylstyrylchinolin.
ATE263771T1 (de) Totalsynthese von acylfulvenen mit antitumorwirkung
DE59408399D1 (de) Arylessigsäurederivate und ihre verwendung als fungizide
ATE178886T1 (de) 1-aryl-2-acylamino-ethan-verbindungen und ihre verwendung als neurokinin- insbesondere als neurokinin-1-antagonisten
DZ1724A1 (fr) Nouvelles azétidinones substituées comme agents anti-inflammatoires et anti-dégénérescence.
CY1108837T1 (el) ΝΕΑ ΠΑΡΑΓΩΓΑ ΑΜΙΝΟΠΥΡΙΔΙΝΗΣ ΩΣ ΑΝΤΑΓΩΝΙΣΤΕΣ mGluR5
TR199901416T2 (xx) Heterosiklik karbonikasit t�revleri.
TR200001080T2 (tr) 2 ile ikame edilmiş 1,2-Benisotiyazol türevleri ve bunların serrotonın antagonistleri
DE69504198D1 (de) Substituierte alkyldiaminderivate und ihre verwendung als tachykinin antagonisten
NO895165D0 (no) Pyrazolopyridin-type mevalono-laktoner.
ATE206050T1 (de) Okulares hypotensium
ATE192443T1 (de) Dithiazoldioxide und ihre verwendung als mikrobizide
ATE340175T1 (de) Imidazo(4,5-böchinolinderivate und ihre verwendung als inhibitoren der induzierbaren no- synthase
DE59905342D1 (de) N-substituierte azabicycloheptan-derivate, ihre herstellung und verwendung

Legal Events

Date Code Title Description
8332 No legal effect for de